Looks like an exciting 2013 from the J.P. Morgan Healthcare Conference

10 of 40

Barbara Fox, CEO of Avaxia Biologics

Avaxia Biologics, developer of orally administered, gut-targeted GI therapeutics, has in the last few months received IND clearance for its lead program, AVX-470, and closed a $6.4 million Series B round. The company's strategy and pipeline have been interesting to investors, CEO Barbara Fox told us, in part because the most effective drugs to treat GI diseases such as inflammatory bowel disease cause systemic immunosuppression over time. AVX-470 has the potential to be safer, as it's delivered right to the gut. The company is poised to begin its first clinical program, a 28-day dosing study.